Legacy Wealth Asset Management LLC Trims Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Legacy Wealth Asset Management LLC lowered its position in BioNTech SE (NASDAQ:BNTX) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,485 shares of the company’s stock after selling 156 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in BioNTech were worth $739,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fred Alger Management LLC purchased a new stake in BioNTech in the third quarter valued at approximately $59,485,000. Baillie Gifford & Co. lifted its stake in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in BioNTech by 63.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after buying an additional 7,340 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after buying an additional 74,119 shares during the last quarter. Finally, Discovery Capital Management LLC CT purchased a new stake in shares of BioNTech during the second quarter worth approximately $2,467,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 0.7 %

BioNTech stock opened at $111.93 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $26.83 billion, a price-to-earnings ratio of -53.30 and a beta of 0.18. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock’s fifty day moving average is $114.69 and its two-hundred day moving average is $104.41.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 earnings per share. Analysts predict that BioNTech SE will post -3.71 EPS for the current fiscal year.

Analysts Set New Price Targets

BNTX has been the subject of several analyst reports. Truist Financial initiated coverage on BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company. HC Wainwright restated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HSBC upped their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, TD Cowen cut their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.